Douglas (Doug) H. Carsten focuses his practice on complex patent litigation disputes. He counsels clients in various technology areas, including pharmaceuticals, biologics, medical devices, diagnostic products, retail products and computer software. He has substantial first-chair trial experience that includes litigating high-profile and billion-dollar patent cases.
Doug is an active speaker on topics relating to patent law, trial practice, Hatch-Waxman issues and oral presentation skills.
Secured a Federal Circuit reversal of a patent term adjustment decision that cost his clients more than a year and a half of patent term relating to the oral pulmonary hypertension drug Orenitram, invalidating a US Patent and Trademark Office (USPTO) regulation that the Federal Circuit had previously affirmed as reasonable (Supernus et al. v. Iancu)*
Secured a trial win on a patent relating to United Therapeutics‘ flagship product, Remodulin. United Therapeutics‘ market capitalization increased approximately $1.2 billion during the trading day in which the US District Court for the District of New Jersey’s decision finding United Therapeutics patent valid and infringed under the doctrine of equivalents was released. (United Therapeutics v. Sandoz)*
Obtained trial verdict finding an injector pen for delivering insulin products did not infringe Sanofi’s patent, and further finding the Sanofi patent invalid (Sanofi-Aventis v. Mylan (D. N.J.))*
Invalidated two formulation patents relating to Sanofi’s blockbuster insulin glargine Lantus product (Mylan v. Sanofi-Aventis (PTO))*
Obtained trial victory invalidating Allergan patents covering the dry-eye treatment, Restasis (Allergan v. Mylan (E.D. TX))*
Obtained jury trial verdict in Boston invalidating a patent relating to drug product testing where the plaintiffs sought nearly $1B in damages (Momenta Pharmaceuticals, Inc. et a. v. Amphastar Pharmaceuticals, Inc. (D. Mass))*
Obtained summary judgment of invalidity in generic-side Hatch-Waxman litigation relating to Pfizer’s blockbuster Celebrex product (D. Searle et al. v. Lupin et al. (E.D. Va.))*
Obtained summary affirmance of district court order enforcing oral settlement agreement resolving Frova litigation (Endo v. Mylan (D. Del.))*
Obtained favorable dismissal of medical device patent litigation (Becton Dickinson v. Medefil (D. NJ))*
Obtained favorable summary judgment ruling of invalidity and unenforceability of two AstraZeneca patents. The invalidity summary judgment was affirmed on appeal (In re Metoprolol Succinate Patent Litigation (E.D. Mo.))*
Obtained favorable summary judgement ruling of non-infringement on one Aventis patent, and a summary judgment dismissing claim of willful infringement on a second Aventis patent. The case was resolved during Cobalt’s presentation of its case-in-chief (Aventis Pharma Deutschland GmbH et al. v. Cobalt Pharmaceuticals (D. Mass.))*
Georgetown University Law Center, JD, cum laude, 1998
Harvard University, MA, Organic Chemistry, 1995
State University of New York at Stony Brook, BS, Chemistry and English Literature, BS with departmental honors, summa cum laude, Phi Beta Kappa, 1993
Courts / Agencies
US Supreme Court
US Court of Appeals for the Federal Circuit
US District Court for the Central District of California
US District Court for the Northern District of California
US District Court for the Southern District of California
US Patent and Trademark Office
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.